Rumors about abbvie buying Endo

Quote

Anonymous

Guest
Any one else hear about abbvie's potential of buying Endo? Kinda makes sense they tried to be in market before, metabolics call on pain specialists, and let's face it we all enjoy pain relief meds every once in a while.
 






























Hey, we already have a sales force that calls on pain people.... it's called Neuro! And while we are expanding (selecting the Best of The Best), it won't be because we have some junk from Endo.
Neuro Rocks Again!

The place to be, because "The Future's So Bright, We Gotta Wear Shades!"
 






Anonymous said:
What next, Abbott buys a research based biotech?
Click to expand...

I think abbott should buy BPAX, for the cost of having a safety study in women for testosterone(Libigel), an approved branded generic testosterone product for men(bio-t-gel) an advancing cancer portfolio in various trail stages at little or no cost (GVAX) and a ton of patents plus other women's health products, elestrien, pill plus ect all for around a billion or do dollars
I believe we should be on it. Libigel and its safety study is probably worth that. Think about it having the womens first TRT product would really cut into the 4 million or so scripts bring compounded annually plus the benifits for CV FSD Plus more. Imagine having the T market pretty well locked up for both sexes and everything else that come with it. No brainer well worth a billion or more.
 






Anonymous said:
Hey, we already have a sales force that calls on pain people.... it's called Neuro! And while we are expanding (selecting the Best of The Best), it won't be because we have some junk from Endo.
Neuro Rocks Again!

The place to be, because "The Future's So Bright, We Gotta Wear Shades!"
Click to expand...

Yeah! Thanks for the CIA too! You fuckers rock...which was never said by any rep.
 
























Anonymous said:
I think you are in denial. There are bigger fish circling around.
Click to expand...

Very few pharma companies have the $60B+ to spend, and the ones that do are uninterested to make deals that large.

The days of the mega-merger are over. Everyone wants the smaller 'bolt-on' deals. No-one wants the mess of untangling two companies after all the big mergers in the last decade turned out not to benefit the purchaser.

Isn't going to happen.
 






That's why it makes sense for us to buy a small biotech like BPAX. Hell we've had people working on the Libigel product for years. BPAX has already took it through the safety trial and has a patent for HRT in women. They also have a cancer portfolio that is moving forward and Bio-T-Gel for low T in men and a shitload of other patents. Just makes sense.
 






Hello to original post ... I work for Endo .. there are only two reasons for Abbvie to by Endo ... a long acting (once every 4-5 months) injection testosterone (Aveed), that has been to phase 3 clinicals and put on the backburner by FDA because of some AE's and is pending for approval after re-submission. The second is for BEMA which is indicated for moderate to severe pain, has a unique delivery system by placing between cheek and gum, and contains buprenorphine..it has currently just moved into the phase 3 clinical stage so possible launch in 2015 IF all goes well. That could be a good product because there is a move that will put all hydrocodone in Schedule II classifications within the next 90 days if voted on as it was in the last 2 weeks in the inital phase for this recommendation. With that move primary care and pain management will be overwhelmed to look for another opioid pain option that doesn't need triplicates! I think the front runner is Valeant in buying Endo but who knows what will happen in this tumultuous industry any longer. Best wishes!
 






Anonymous said:
That's why it makes sense for us to buy a small biotech like BPAX. Hell we've had people working on the Libigel product for years. BPAX has already took it through the safety trial and has a patent for HRT in women. They also have a cancer portfolio that is moving forward and Bio-T-Gel for low T in men and a shitload of other patents. Just makes sense.
Click to expand...

I think an Abbvie/BPAX licensing agreement is already in place ready to be formalized when BPAX and ANI merge.

This would explain the following Phase II trial The VO2 Increase With Testosterone Addition - Heart Failure (VITA-HF) Trial using Androgel for treatment of men and an unnamed low dose 300 mg testosterone gel for treatment of women. Libigel is the only product with the supporting safety profile to use on Heart Failure patients

http://www.clinicaltrials.gov/ct2/show/NCT01469988?term=NCT01469988&rank=1
 






Top Bottom
Back
Quote